Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


News Briefs: Medtronic’s First-Gen Artificial Pancreas Approved; CMS Removes Bariatric Surgery Requirements

This article was originally published in The Gray Sheet

Executive Summary

FDA approves Medtronic’s MiniMed 530G system, making it the first system in the U.S. that can automatically suspend insulin delivery to people with diabetes. CMS removes bariatric surgery facility certification requirements. More news.

You may also be interested in...

People Briefs: MDMA Board Adds; Appointments At Insulet, MedLumics, Cardiva, Cardica

Industry veteran Jim Mazzo joins Medical Device Manufacturers Association board, along with three others. Insulet, MedLumics, Cardiva and Cardica announce appointments. More people briefs.

Insulin Pumps, Including Sensor-Augmented, Enter Competitive Bidding

Now that insulin pumps are part of CMS’ competitive bidding program, there is a possibility of reimbursement reductions down the road. And in a separate process, CMS denied Medtronic’s request to establish a new HCPCS code for sensor-augmented insulin pumps.

Medtronic Anticipates Turnaround For Challenged Business Units

Executives focused on new developments in the company’s ICD, spine, neuromodulation, and diabetes product lines, which have each faced particular challenges over the past year, during Medtronic’s second-quarter fiscal 2014 earnings call.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts